Objectives: To report on the pharmacology, efficacy and safety of omalizumab , a new option for the treatment of asthma and allergic diseases and the first monoclonal anti-IgE antibody approved for clinical use.
Introduction
Immunoglobulin E (IgE) is the key molecule in immediate allergic reactions. It was identified in 1966, when Ishizaka confirmed that the reagin involved in anaphylactic reactions was, in fact, an immunoglobulin, IgE. The delay in making this discovery is due to the fact that IgE is a cytophilic antibody with serum concentrations so low that they were not detectable by the techniques available at the time. 1, 2 After allergen exposure, during the sensitization phase, IgE can be detected in serum soon after it is synthesized by plasmacytes, but the greatest concentration is to be found fixed in basophils and mast cells by high-affinity receptors (FcεRI). These receptors capture IgE by means of the third domain of the heavy chain constant region (CH3). When contact with the antigen occurs once more, the effector phase begins, with the formation of a bridge that permits a bivalent bond between two immunoglobulin E molecules and the allergen. This process triggers cellular degranulation, with liberation of countless preformed mediators and cytokines. 2 Even though IgE has been known about for more than 30 years, its natural function in biological terms remains a mystery. It is known that, in several types of helminthiasis, serum IgE titers are extremely elevated; however there are doubts whether this increase reflects a role in the defense against intestinal worms or whether it is simply an escape mechanism used by the parasites, originating from interleukin 4 overproduction (IL4) with a resultant polyclonal nonfunctional increase in IgE. 3, 4 Despite doubts about the true biological function of IgE in relation to the pathological process of the allergy, this immunoglobulin is recognized as the central inductive factor in the anaphylactic process. Therefore, neutralization or inhibition of IgE synthesis could be a rational option for the treatment of allergic diseases. 1 IgE specific antibody 5%
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One wish of researchers working on the subject has been to employ an anti-IgE, since there is an evident biological rationale for this: it would act before symptoms appear, providing a preventative action prior to the inflammatory process and a direct action against the target of the allergic process. 2, 6 As the concept of an antiIgE matured, an antibody was synthesized in laboratory that has does not trigger the allergenic inflammatory process. 7 The molecule synthesized was to exhibit high affinity for both serum IgE and recently-synthesized IgE, which is still fixed in the lymphocyte B membrane. On the other hand it had to be inactive with respect to IgE bonded to high-affinity receptors (FcεRI) fixed in the surface of basophil and mast cell membranes, and also should not recognize IgE bonded to low-affinity receptors (FcεRII or CD23), which are abundantly distributed across several different types of cell. [8] [9] [10] [11] Tests with laboratory animals and clinical trials corroborated these properties, which had been established as goals for the molecular engineering that resulted in the synthesis of omalizumab. [9] [10] [11] Omalizumab, as a nonanaphylactic synthetic antibody, Table 2 -Total recommended 4 week omalizumab dosages, according to total serum IgE levels and body weight. The medication is packaged in 150 mg phials and no more than 150 mg should be given per injection site, neither should more than 300 mg be given on a single day. When more than 300 mg per month is necessary, the dosage should be subdivided and given every 2 weeks produced. 14 Pharmacokinetic studies with human beings demonstrated that there is no need to adjust dosage for sex, race or age in patients over 12 years old. 19, 20 After the product is administered, there is an increase in total serum IgE levels due to the delay in eliminating IgEomalizumab immunocompounds. Nevertheless, total free IgE levels in serum drop dramatically in more than 96% of cases 1 hour after the medication is given. These levels are maintained with continued application of the product. 10 In human beings, the product is very well tolerated by the majority of patients, permitting an accentuated drop in total free serum IgE concentration for 4 to 6 weeks, due to its extended half-life with a single subcutaneous injection.
This is explained by the fact that anti-IgE is an immunoglobulin of the IgG1 isotype, which is eliminated slowly by the cells of the reticuloendothelial system in the hepatic sinusoids hepatic sinusoids. 10, 12, 13, 15 Clinical studies of prolonged use demonstrate that there is a reduction in the number of high-affinity receptors on the surface of basophils, in addition to reductions in expression of low-affinity receptors in other inflammatory cells. 21 Certain precautions should be taken with patients on omalizumab. It should be stressed that the product is not indicated for acute episodes of asthma, and even when response to the product is good, untimely withdrawal of corticoids should be avoided. It is important to remember that the physician should employ the correct dose (0.016 mg/kg/level of total IgE in UI/mL), as recommended in Table 2 , for the treatment to be effective. Among the countless variables studied, the weight of the patient and initial total IgE level were the most important factors for defining the omalizumab dose needed to achieve response to the treatment. 10 It may take up to 12 to 16 weeks for the clinical effect of the medication to be observed. After this period, patients who do not exhibit improvement in symptoms and quality of life should seek another therapeutic option. Studies to evaluate omalizumab in patients under 12 years old are currently ongoing. [10] [11] [12] 15 The effect of omalizumab correlated with total free IgE dropping to below 50 ng/mL. The goal of treatment is to obtain an omalizumab dose, based on the level of total IgE, which is sufficient to reduce the level of total free IgE to around 25 ng/mL in more than 95% of the patients. 10, 21 omalizumab also improves the efficacy and safety of immunotherapy. It is possible that in the future, it will be used in association with that approach to promote improved clinical tolerance and advances in the time of this type of treatment, both for asthma and allergic rhinitis. 12, 22, 23 Clinical use of omalizumab has raised certain questions that have not yet been completely elucidated. Although the reduction in total free IgE is followed by rapid improvement in some patients, in others clinical improvement is delayed, or, sometimes does not occur, even when total free IgE is reduced to zero. [22] [23] [24] Use in severe asthma
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to low and high-affinity receptors in mast cells and basophils, represents one more step in the treatment of asthma and other IgE-mediated diseases. 10, [20] [21] [22] 24 Omalizumab was developed to treat allergic disease, and offers recognized efficacy for the treatment of moderate and severe asthma and for the treatment of seasonal or perennial treatment. However, the currently established recommendation is for severe cases of refractory asthma. 12,15,22 omalizumab inhibits the early and late phases of the allergen-induced asthmatic and prevents the development of eosinophilia and bronchial hyperreactivity. 12 Studies conducted on patients with moderate and severe asthma demonstrated a reduction in corticosteroid use and in asthma exacerbations when omalizumab was given intravenously. [25] [26] [27] Other studies that used subcutaneous omalizumab at the Standard dose of 0.016 mg/kg per UI/mL of serum IgE every 4 weeks also demonstrated reductions in inhaled corticosteroid use, in symptoms and in the use of emergency medication. [28] [29] [30] In three further studies, the frequency of a asthma exacerbations, defined as increase in inhaled corticosteroid dose or treatment with oral or intravenous corticosteroid, reduced significantly when compared with placebo groups.
The same studies further reported reductions in the use of emergency medication and improved quality of life. [31] [32] [33] omalizumab has consistently been related to improvements in severe uncontrolled asthma patients, both in terms of asthma symptoms, with improved tolerance of exposure to the environment, and also in terms of daily activity and emotional wellbeing. A study that used subcutaneous omalizumab with severe asthma sufferers on high dose inhaled corticosteroids associated with long acting bronchodilators (LABA), demonstrated reductions in episodes of exacerbation, severity of exacerbations and emergency room visits. 34 Holgate et al., 24 in a double-blind, randomized, placebo controlled study, investigated patients with severe asthma, on high dose inhaled corticosteroids. In the group that used omalizumab there was a significant reduction in inhaled steroid use, in acute exacerbations, emergency bronchodilator consumption and evident improvements in quality of life.
The efficacy of omalizumab has also been investigated with patients suffering from severe asthma and on oral corticosteroids with anti-leukotrienes and LABA.
Omalizumab significantly reduced deterioration, thus demonstrating that associating this monoclonal antibody to the standard treatment of patients with severe asthma and poor control of symptoms can be of real benefit. 17 A clinical trial involving 1,405 patients with moderate and severe asthma demonstrated that anti-IgE reduced the rate of severe exacerbations and reduced emergency service usage and hospitalizations. 35 According to a systematic Cochrane review, omalizumab was capable of exhibiting a reductive effect on steroid use, but that the advantage of that effect should be evaluated in terms of its cost/benefit ratio. Further studies into this aspect are needed, especially ones including pediatric patients. 36 Currently, omalizumab is licensed in the United States for patients over 12 years old with persistent moderate or severe asthma who have a positive skin test or in vitro test for an aeroallergen, with poor control using inhaled steroids, and whose total IgE in serum is from 30 to 700 UI/mL. 13, 21, 37 In the European Community and Brazil, approval is limited to the treatment of severe asthma.
Use for allergic rhinitis
It has been demonstrated that systemic treatment with omalizumab reduced symptoms and caused improved quality of life in patients with moderate/severe allergic rhinitis. 38 Studies conducted by Plewako et al. 39 Use for anaphylactic shock and food allergy
There have been no studies of the applicability of omalizumab in cases of IgE-mediated food intolerance reactions. However, studies using a different anti-IgE, administered experimentally to humans, found increased tolerance of peanuts in patients subject to anaphylactic reactions to the food, which could prevent severe reactions in cases of accidental ingestion. 46 This could be an additional indication for omalizumab if the same property can be confirmed, since it is the anti-IgE that is approved for sale and use with human beings.
Safety of the medication in children
Despite the advances in diagnosis and therapy during recent years, the prevalence of asthma in children has increased significantly. In a double-blind, placebo controlled study of patients aged 6 to 12 years of age and on regular inhaled corticosteroids and short-action bronchodilators, omalizumab used at the standard dose of 0.016mg/kg/ IgE(UI/mL) every 4 weeks led to a reduction in inhaled corticosteroid use and also in total free IgE in serum levels. 47 The most common adverse events associated with omalizumab were headaches and upper airway [48] [49] [50] Nevertheless, further studies are needed to increase the number of children observed.
Tolerability
The most frequently observed adverse events in studies with omalizumab were headaches, affecting from 1 to 10% of patients, and local reactions at the injection site, such as pain, edema, erythema and itching. Uncommon events, occurring in less than 1% of patients, were weight gain, postural hypotension, dizziness, somnolence, paresthesia, pharyngitis, paradoxical bronchospasm, nausea, diarrhea, dyspepsia and cutaneous effects such as reddening, urticaria, exanthema, itching, edema of lower members and photosensitization. 51 The possibility of parasitic infections and anaphylactic shock were considered rare events, with frequencies of less than 1 in every 1,000 patients who used the product. 52 Anaphylactic reactions that have been reported with omalizumab are rare and, in general, take place within the 
